Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases

Sedef,Ali  Murat; Köse,Fatih; Doğan,Özlem; Ergün,Tarkan; Sezer,Ahmet; Mertsoylu,Hüseyin; Muallaoğlu,Sadık; Beşen,Ayberk; Özyılkan,Özgur

doi:10.3892/mco.2014.456

March-2015 Volume 3 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2015 Volume 3 Issue 2

Full Size Image

Article

Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases

Authors:
- Ali Murat Sedef
- Fatih Köse
- Özlem Doğan
- Tarkan Ergün
- Ahmet Sezer
- Hüseyin Mertsoylu
- Sadık Muallaoğlu
- Ayberk Beşen
- Özgur Özyılkan
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Baskent University Adana Hospital, Yuregır, Adana, Turkey, Department of Internal Medicine, Baskent University Adana Hospital, Yuregır, Adana, Turkey, Department of Radiology, Baskent University Adana Hospital, Yuregır, Adana, Turkey
Pages: 400-402
|
Published online on: November 13, 2014

https://doi.org/10.3892/mco.2014.456
Expand metrics +

Abstract

Soft tissue sarcomas (STS) are a group of rare mesenchymal cancers that include approximately 50 histological types and account for 1% of all adult cancers. The standard curative treatment option for localized disease is surgical resection and, if a surgically removed tumor exhibits high‑risk characteristics, adjuvant chemotherapy and radiotherapy may be administered. Sarcoma presenting at an advanced stage has a dismal prognosis and survival has not markedly improved over the last 20 years. The standard first-line treatment for advanced sts, other than gastrointestinal stromal tumors, is cytotoxic chemotherapy. Therapies targeting pro‑angiogenic factors have been a focus of drug development for STS over the last few years. Pazopanib, a multitargeted tyrosine kinase inhibitor, is a novel treatment option for patients with metastatic sts in the second‑line setting. This is a presentation of 2 case reports of patients with metastatic sts who responded well to treatment with pazopanib.

View Figures

View References

1	Clark MA, Fisher C, Judson I and Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med. 353:701–711. 2005. View Article : Google Scholar : PubMed/NCBI
2	Casali PG and Blay JYESMO/CONTICANET/EUROBONET Consensus Panel of Experts: Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 (Suppl 5):v198–v203. 2010. View Article : Google Scholar : PubMed/NCBI
3	Cormier JN and Pollock RE: Soft tissue sarcomas. CA Cancer J Clin. 54:94–109. 2004. View Article : Google Scholar : PubMed/NCBI
4	Jain A, Sajeevan KV, Babu KG and Lakshmaiah KC: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer. 46:274–287. 2009. View Article : Google Scholar : PubMed/NCBI
5	Weiss SW and Goldblum JR: General considerationsEnzinger and Weiss's Soft Tissue Tumors. Weiss SW and Goldblum JR: 4th. CV Mosby; St. Louis, MO: pp. 1–19. 2001
6	Schöffski P: Pazopanib in the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther. 12:711–723. 2012. View Article : Google Scholar : PubMed/NCBI
7	Italiano A, Mathoulin-Pelissier S, Cesne AL, Terrier P, Bonvalot S, Collin F, Michels JJ, Blay JY, Coindre JM and Bui B: Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 117:1049–1054. 2011. View Article : Google Scholar : PubMed/NCBI
8	Grimer R, Judson I, Peake D and Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010:5061822010. View Article : Google Scholar : PubMed/NCBI
9	Spira AI and Ettinger DS: The use of chemotherapy in soft-tissue sarcomas. Oncologist. 7:348–359. 2002. View Article : Google Scholar : PubMed/NCBI
10	NCCN, . NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, Volume V.1. 2011. National Comprehensive Cancer Network; 2011
11	Schutz FA, Choueiri TK and Sternberg CN: Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol. 77:163–171. 2011. View Article : Google Scholar : PubMed/NCBI
12	Sleijfer S, Ray-Coquard I, Papai Z, et al: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 27:31262009. View Article : Google Scholar : PubMed/NCBI
13	Van der Graaf WT, Blay JY, Chawla SP, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
14	Van Der Graaf W, Blay JY, Chawla SP, et al: PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized, double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients. J Clin Oncol. 30:abs. 100092012.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles